Walleye Capital
MRVI icon

Walleye Capital’s Maravai LifeSciences MRVI Stock Holding History

Walleye Capital’s Portfolio MRVI Stock Details MRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-62,313
Closed -$150K – 4885
2025
Q2 		$150K Sell
62,313
-168,687
-73% -$355K ﹤0.01% 3558
2025
Q1 		$511K Buy
+231,000
New +$913K ﹤0.01% 2544
2023
Q4 		– Sell
-19,170
Closed -$192K – 5310
2023
Q3 		$192K Buy
19,170
+47
+0.2% +$516 ﹤0.01% 3582
2023
Q2 		$238K Buy
+19,123
New +$258K ﹤0.01% 2976
2022
Q2 		– Sell
-24,320
Closed -$858K – 2581
2022
Q1 		$858K Buy
+24,320
New +$815K 0.02% 707
2021
Q4 		– Sell
-8,163
Closed -$401 – 2238
2021
Q3 		$401 Sell
8,163
-22,483
-73% -$1.1M 0.01% 888
2021
Q2 		$1.28K Buy
+30,646
New +$1.19M 0.04% 351
2021
Q1 		– Sell
-170,399
Closed -$4.78K – 1277
2020
Q4 		$4.78K Buy
+170,399
New +$4.75M 0.32% 43

Other funds holding MRVI

GL
GTCR LLC Chicago, Illinois $3.78B AUM 27.82% 1-Year Est. Return
1WCM
12 West Capital Management New York $592M AUM 40.75% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
MFS
Mirabella Financial Services London, United Kingdom $1.06B AUM 19.83% 1-Year Est. Return
MAM
Monaco Asset Management Monaco $542M AUM 54.4% 1-Year Est. Return

Walleye Capital's MRVI Position: Q3 2025 in Review

Walleye Capital sold out of Maravai LifeSciences (MRVI) in Q3 2025, closing a stake of 62,313 shares — an estimated $150K sold.

Walleye Capital first reported a position in MRVI in Q4 2020 and held it in 8 quarters. The position peaked at $858K in Q1 2022. 160 funds tracked by Wall St. Rank hold MRVI as of Q3 2025.

  • Walleye Capital reported no remaining Maravai LifeSciences position as of Q3 2025 after selling out during the quarter.
  • Walleye Capital sold 62,313 Maravai LifeSciences shares in Q3 2025, an estimated $150K.
  • Walleye Capital first reported a position in Maravai LifeSciences in Q4 2020 and held it in 8 quarters.
  • Walleye Capital's Maravai LifeSciences position peaked at $858K in Q1 2022.
  • 160 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q3 2025.

Based on Walleye Capital's 13F filing for Q3 2025, filed 14 Nov 2025.